Mesoblast (NASDAQ:MESO) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Mesoblast Limited (NASDAQ:MESO) shares crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $18.19 and traded as low as $16.50. Mesoblast shares last traded at $16.67, with a volume of 144,397 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Mesoblast presently has a consensus rating of “Moderate Buy”.

Mesoblast Stock Performance

The company has a current ratio of 1.99, a quick ratio of 1.77 and a debt-to-equity ratio of 0.11. The business’s 50 day moving average is $18.19 and its 200 day moving average is $16.81. The stock has a market capitalization of $2.15 billion, a PE ratio of -18.94 and a beta of 2.15.

Institutional Investors Weigh In On Mesoblast

Hedge funds and other institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. purchased a new position in Mesoblast during the 1st quarter valued at $3,209,000. Vanguard Personalized Indexing Management LLC increased its stake in Mesoblast by 27.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,331 shares of the company’s stock worth $145,000 after purchasing an additional 2,832 shares during the period. R Squared Ltd bought a new stake in shares of Mesoblast during the second quarter worth $126,000. Summit X LLC lifted its position in shares of Mesoblast by 0.6% during the second quarter. Summit X LLC now owns 199,295 shares of the company’s stock worth $2,170,000 after purchasing an additional 1,132 shares during the last quarter. Finally, Creative Planning purchased a new stake in shares of Mesoblast during the second quarter valued at $141,000. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.